Alkermes Showcases Research From Psychiatry and Sleep Portfolios at the Neuroscience Education Institute Fall CongressBusiness Wire • 11/05/26
Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to SayZacks Investment Research • 11/03/26
Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD)Business Wire • 10/30/26
Alkermes Q3 Preview: The Pipeline Looks Strong, But Earnings Tell Another StorySeeking Alpha • 10/29/26
Earnings Preview: Alkermes (ALKS) Q3 Earnings Expected to DeclineZacks Investment Research • 10/20/26
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine ResearchBusiness Wire • 10/13/26
Alkermes: Idiopathic Hypersomnia Could Expand Lumryz Into A Larger Growth And Margin DriverSeeking Alpha • 09/26/26
Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290Zacks Investment Research • 09/22/26
How Alkermes Used Its Narcolepsy Playbook In ADHD — And Seemingly WonInvestors Business Daily • 09/21/26
Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)Business Wire • 09/21/26
Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® ProgramBusiness Wire • 09/10/26
The Lancet Neurology Publishes Data From Alkermes' Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1Business Wire • 08/24/26